had reviewed the minutes, and they appeared to be substantially 
correct and moved their adoption. 
Dr. Walters seconded the motion and added that he believed three 
minor corrections to the minutes were in order. The first 
correction to be made was on page 4 of the minutes, and 
Dr. Walters suggested the wording, "public members having 
previously submitted written documents" be replaced with "members 
of the public who had submitted written documents." The second 
correction was on page 6, where Dr. Walters suggested that the 
clause, "covering respectively animals, microorganisms other than 
vaccines and vaccines," should be reworded to "covering 
respectively animals, microorganisms other than those used in 
vaccines, and vaccines." The final correction noted was a 
typographical error in the word "recombinant" on page 19. He 
added that with these three very technical revisions that he 
believed the minutes did an admirable job of capturing the 
meeting. 
Dr. Musgrave said he agreed with the corrections that Dr. Walters 
had offered and amended his motion to include them. Dr. Walters 
seconded the motion. Mr. Mitchell called for a vote on the 
motion, and it was passed unanimously by voice vote. 
III. REPORT FROM THE HUMAN GENE THERAPY SUBCOMMITTEE (tabs 1297, 1298, 
1303 ) . 
The RAC Human Gene Therapy Subcommittee had met on April 24, 
1987. An initial review of a preclinical data document submitted 
by Dr. French Anderson and colleagues and a document intended to 
be a layman's guide to human gene therapy were the two items of 
business which were discussed. 
Dr. Walters said that the preclinical document was prepared as a 
result of an invitation sent by Dr. Gartland to U.S. research 
groups in 1986 who were known to be working toward gene therapy. 
The document invited them to test the fit of state-of-the-art 
laboratory research in this field to the Points to Consider 
document which had been approved by the RAC. 
The document, "Human Gene Therapy: Preclinical Data Document," 
was coordinated by Dr. French Anderson of the National Heart, 
Lung, and Blood Institute ( NHLBI ) together with researchers from 
the Memorial Sloan-Kettering Cancer Center in New York City who 
are his collaborators. The document is 86 pages in length and is 
accompanied with 360 pages of appendices. 
Dr. Walters noted that Dr. Anderson and his colleagues raised 
three central questions as to the current status of laboratory 
research related to gene therapy: 
Recombinant DNA Research, Volume 13 
[45] 
